March 1, 2024 07:04 AM EST

Pfizer names a VC leader in year of reset; Former Axcella CEO moves on after company shutdown

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ A spokesperson for Pfizer tells Peer Review that Michael Diem has joined the pharma giant as head of venture capital & equity investments. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer names a VC leader in year of reset; Former Axcella CEO moves on after company shutdown

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pfiz­er names a VC leader in year of re­set; For­mer Ax­cel­la CEO moves on af­ter com­pa­ny shut­down

Copy Chief

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pfizer names a VC leader in year of reset; Former Axcella CEO moves on after company shutdown